Keytruda killer Ivonescimab valued at $17B pre-approval.
Yet PD-1/VEGF bispecifics do not activate T cells or make cold tumors hot.When PD-1/VEGF hit wall, dendritic cells prime & heat the tumor activating T cells enabling bispecifics to work.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $365.0M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.3¢ | 24.5¢ | $620.5K | 2.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 66277 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22044 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| IMM (ASX) Chart |